{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:54:34Z","timestamp":1772117674377,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd005642.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000}}],"reference-count":125,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005642.pub3","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T08:41:43Z","timestamp":1393576903000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C"],"prefix":"10.1002","volume":"2014","author":[{"given":"Goran","family":"Hauser","sequence":"first","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51 000"},{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Department 7812, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahany","family":"Awad","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Department 7812, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Thorlund","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Clinical Epidemiology and Biostatistics; Hamilton Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davor","family":"\u0160timac","sequence":"additional","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51 000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahasen","family":"Mabrouk","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Cairo University; Endemic Medicine and Liver Department; Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Department 7812, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/j.gastro.2009.10.005","article-title":"Peginterferon alfa-2a plus ribavirin Is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection","volume":"138","author":"Ascione","year":"2010","journal-title":"Gastroenterology"},{"issue":"S2","key":"10.1002\/14651858.CD005642.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0168-8278(08)60992-7","article-title":"Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver","volume":"48","author":"Ascione","year":"2008","journal-title":"Hepatology"},{"issue":"4 S1","key":"10.1002\/14651858.CD005642.pub3-BIB0003|cit3","first-page":"684A","article-title":"Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2\/3 genotypes-12 week virological response analysis","volume":"42","author":"Berak","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005642.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/135965350400900405","article-title":"Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study","volume":"9","author":"Bruno","year":"2004","journal-title":"Antiviral Therapy"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/135965350501000201","article-title":"Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C","volume":"10","author":"Bruno","year":"2005","journal-title":"Antiviral Therapy"},{"issue":"3","key":"10.1002\/14651858.CD005642.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2036.2007.03392.x","article-title":"Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-na\u00efve patients with chronic hepatitis C: a randomized, controlled study","volume":"26","author":"Bruno","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD005642.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2893.2007.00862.x","article-title":"Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C","volume":"14","author":"Bisceglie","year":"2007","journal-title":"Viral Hepatitis"},{"issue":"S4","key":"10.1002\/14651858.CD005642.pub3-BIB0008|cit8","first-page":"734A","article-title":"Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2A or alfa-2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C","volume":"40","author":"Bisceglie","year":"2004","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1478-3231.2010.02435.x","article-title":"Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis","volume":"31","author":"Kamal","year":"2011","journal-title":"Liver International"},{"issue":"4","key":"10.1002\/14651858.CD005642.pub3-BIB0010|cit10","first-page":"1278","article-title":"Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study","volume":"48","author":"Kolakowska","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.22598","article-title":"Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients","volume":"49","author":"Laguno","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0012|cit12","first-page":"434","article-title":"Efficacy of pegylated interferon alfa\u20112aor alfa\u20112b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b","volume":"121","author":"Mach","year":"2011","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","article-title":"Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C","volume":"140","author":"Marcellin","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD005642.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD005642.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00535-012-0560-9","article-title":"Randomized trial of peginterferon a-2a plus ribavirin versus peginterferon a-2b plus ribavirin for chronic hepatitis C in Japanese patients","volume":"47","author":"Miyase","year":"2012","journal-title":"Journal of Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005642.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/S0168-8278(12)61154-4","article-title":"PEGIFNalpha-2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha-2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL-28B major allele","volume":"56","author":"Miyase","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005642.pub3-BIB0017|cit17","first-page":"A212","article-title":"Randomized study comparing peginterferon-alfa2a plus ribavirin and peginterferon-alfa2b plus ribavirin in na\u00efve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study","volume":"48","author":"Rumi","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2009.08.071","article-title":"Randomized study of peginterferon-\u221d2a plus ribavirin vs peginterferon-\u221d2b plus ribavirin in chronic hepatitis C","volume":"138","author":"Rumi","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD005642.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200868060-00005","article-title":"Early and sustained virological response in non-responders with chronic hepatitis C; a randomized open-label study of pegylated interferon-\u03b1-2a versus pegylated interferon-\u03b1-2b","volume":"68","author":"Scotto","year":"2008","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"623\u201330","DOI":"10.1089\/jir.2007.0116","article-title":"Peg-interferon alpha-2a versus peg-interferon alpha-2b in non responders with HCV active chronic hepatitis: A pilot study","volume":"28","author":"Scotto","year":"2008","journal-title":"Interferon and Cytokine Research"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jhep.2006.03.008","article-title":"A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)","volume":"45","author":"Silva","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2008.05.009","article-title":"Compare trial: Updated data","volume":"49","author":"Silva","year":"2008","journal-title":"Hepatology"},{"issue":"4 S1","key":"10.1002\/14651858.CD005642.pub3-BIB0023|cit23","first-page":"192A","article-title":"Comparison of peginterferon-alpha2a and peginterferon-alpha2B pharmacokinetics and pharmacodynamic in compare, a randomized, prospective, blinded trial","volume":"40","author":"Silva","year":"2004","journal-title":"Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD005642.pub3-BIB0024|cit24","first-page":"237","article-title":"A randomized prospective clinical trial comparing pegylated interferon alpha 2a\/ribavirin versus pegylated interferon alpha 2b\/ribavirin in the treatment of chronic hepatitis C","volume":"99","author":"Sinha","year":"2004","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0025|cit25","unstructured":"Sporea I Danila M Sirli R Popescu A Laza A Baditoiu L Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis Journal of Gastrointestinal and Liver Diseases 2006 125 30"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0026|cit26","first-page":"94","article-title":"The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients","volume":"17","author":"Yenice","year":"2006","journal-title":"Turkish Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD005642.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/135965350601100403","article-title":"Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels","volume":"11","author":"Andrade","year":"2006","journal-title":"Antiviral Therapy"},{"issue":"3","key":"10.1002\/14651858.CD005642.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"A71","DOI":"10.1016\/S1098-3015(10)72336-6","article-title":"Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with genotypes 2\/3 chronic hepatitis C under the public payer perspective in Brazil","volume":"13","author":"Barros","year":"2010","journal-title":"Value in Health"},{"issue":"3","key":"10.1002\/14651858.CD005642.pub3-BIB0029|cit29","first-page":"A72","article-title":"Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with genotype 1 chronic hepatitis C under the public payer perspective in Brazil","volume":"13","author":"Barros","year":"2010","journal-title":"Value in Health"},{"issue":"5","key":"10.1002\/14651858.CD005642.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2893.2005.00680.x","article-title":"Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients","volume":"13","author":"Bruchfeld","year":"2006","journal-title":"Journal of Viral Hepatology"},{"issue":"S2","key":"10.1002\/14651858.CD005642.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0168-8278(06)80563-5","article-title":"Comparison between the two peginterferon's a in the treatment of chronic hepatitis C","volume":"44","author":"Cozzolongo","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"48","key":"10.1002\/14651858.CD005642.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0168-8278(08)60782-5","article-title":"Predictors of SVR in na\u00efve HCV G1 patients in real life practice: the probe","volume":"2","author":"Craxi","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e100694","DOI":"10.5812\/hepatmon.10069","article-title":"The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: A single centre Egyptian study","volume":"13","author":"Raziky","year":"2013","journal-title":"Hepatitis Monthly"},{"issue":"6","key":"10.1002\/14651858.CD005642.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1440-1746.2008.05397.x","article-title":"Pegylated interferon-2a plus ribavirin compared with pegylated interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non-randomized study","volume":"23","author":"Escudero","year":"2008","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5414\/CNP67366","article-title":"Anemia associated with pegylated interferon-alpha 2a and alpha 2b therapy in haemodialysis patients","volume":"67","author":"Espinosa","year":"2007","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-2005-858960","article-title":"Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists","volume":"44","author":"Hofmann","year":"2006","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000274975","article-title":"Efficacy and tolerability of pegylated interferon-alpha 2a plus ribavirin versus pegylated interferon- alpha 2b plus ribavirin in treatment-naive chronic hepatitis C patients","volume":"53","author":"Lee","year":"2010","journal-title":"Intervirology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2893.2011.01525.x","article-title":"Comparative trials of peginterferon alpha 2a and peginterferon alpha 2b for chronic hepatitis C","volume":"19","author":"Rumi","year":"2012","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"640\u20139","DOI":"10.1111\/j.1365-2893.2012.01593.x","article-title":"Peginterferon-A 2B plus ribavirin is more effective than peginterferon-A 2A plus ribavirin in menopausal women with chronic hepatitis C","volume":"19","author":"Villa","year":"2012","journal-title":"Journal of Viral Hepatitis"},{"issue":"S2","key":"10.1002\/14651858.CD005642.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0168-8278(08)60842-9","article-title":"Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: The practice study. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver","volume":"48","author":"Witthoeft","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep.23000","article-title":"Effect of hepatitis C virus and its treatment on survival","volume":"50","author":"Adeel","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0042|cit42","first-page":"121","article-title":"The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis","volume":"10","author":"Alavian","year":"2010","journal-title":"Hepatitis Monthly"},{"issue":"7","key":"10.1002\/14651858.CD005642.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of interferon: a 40\u00a0kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconjugate Chemistry"},{"issue":"9654","key":"10.1002\/14651858.CD005642.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(08)61560-3","article-title":"Perioperative \u03b2 blockers in patients having non-cardiac surgery: a meta-analysis","volume":"372","author":"Bangalore","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"A368","DOI":"10.1016\/S1098-3015(11)72485-8","article-title":"Is there any difference between the effects of therapy with peginterferon-alpha-2a versus standard-dose peginterferon-alpha-2b? A meta-analysis comparing both treatments plus ribavirin in genotype 1\/4 chronic hepatitis C virus (HCV) infection patients","volume":"13","author":"Barros","year":"2010","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0166-3542(01)00185-1","article-title":"Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus-related cirrhosis","volume":"52","author":"Benvegnu","year":"2001","journal-title":"Antiviral Research"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005445","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD005642.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"A69","DOI":"10.1016\/S1098-3015(10)72324-X","article-title":"Systematic review and meta-analysis of published randomised controlled trials comparing the efficacy of peginterferon-alpha-2a versus peginterferon alpha-2b both plus ribavirin in chronic hepatitis C patients","volume":"13","author":"Cheinquer","year":"2010","journal-title":"Value in Health"},{"issue":"Suppl","key":"10.1002\/14651858.CD005642.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/S1590-8658(11)60091-1","article-title":"Efficacy and tolerability of peginterferon \u03b1-2a and \u03b1-2b in patients with chronic hepatitis C by genotype 1: A meta-analysis","volume":"43","author":"Coppola","year":"2011","journal-title":"Digestive and Liver Diseases"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0054|cit54","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis ctu.dk\/tsa\/"},{"issue":"6B","key":"10.1002\/14651858.CD005642.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/S0002-9343(99)00376-9","article-title":"Hepatitis C virus genotypes and quasi species","volume":"107","author":"Davis","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005642.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods of combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005642.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hep.24169","article-title":"Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon","volume":"53","author":"Bisceglie","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0059|cit59","first-page":"11","article-title":"Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis","volume":"5","author":"Druyts","year":"2012","journal-title":"Clinical and Experimental Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"European Association for the Study of the Liver, EASL Clinical Practice Guidelines: Management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD005642.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"11","key":"10.1002\/14651858.CD005642.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/ajg.2010.294","article-title":"Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response","volume":"105","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-013-0027-1","article-title":"Pegylated interferon-a2a and ribavirin versus pegylated interferon-a2b and ribavirin in chronic hepatitis C. A meta-analysis","volume":"73","author":"Flori","year":"2013","journal-title":"Drugs"},{"issue":"8","key":"10.1002\/14651858.CD005642.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2036.2004.02170.x","article-title":"Pegylated interferons: chemical and clinical differences","volume":"20","author":"Foster","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0066|cit66","first-page":"975\u201382","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Human Services"},{"issue":"4","key":"10.1002\/14651858.CD005642.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"1433\u201344","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005642.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data","volume":"68","author":"Glue","year":"2000","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD005642.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0071|cit71","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2013, Issue 12. Art. No.: LIVER"},{"issue":"12","key":"10.1002\/14651858.CD005642.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e83313","DOI":"10.1371\/journal.pone.0083313","article-title":"Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?","volume":"8","author":"Gurusamy","year":"2014","journal-title":"PLoS ONE"},{"issue":"7650","key":"10.1002\/14651858.CD005642.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"346\u201355","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD005642.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0076|cit76","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/hep.23002","article-title":"Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study","volume":"50","author":"Hirofumi","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0078|cit78","article-title":"Viral hepatitis - clinical aspects","volume-title":"Oxford Textbook of Medicine","author":"Hodgson","year":"2003"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000006.pub3","article-title":"Publication bias in clinical trials due to statistical significance or direction of trial results","author":"Hopewell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0081|cit81","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/jama.294.2.218","article-title":"Contradicted\u00a0and\u00a0initially\u00a0stronger\u00a0effects\u00a0in\u00a0highly\u00a0cited\u00a0clinical\u00a0research","volume":"294","author":"Ioannidis","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD005642.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Medicine"},{"issue":"11","key":"10.1002\/14651858.CD005642.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003617.pub2","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Koretz","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0086|cit86","first-page":"247","article-title":"Therapy and validity: surprising results of randomized controlled trials","volume-title":"Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice","author":"Lacchetti","year":"2002"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0895-4356(94)00106-Z","article-title":"Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care","volume":"48","author":"Lau","year":"1995","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD005642.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1371\/journal.pmed.0050191","article-title":"Publication of clinical trials supporting successful new drug applications: A literature analysis","volume":"5","author":"Lee","year":"2008","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"12","key":"10.1002\/14651858.CD005642.pub3-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9286","key":"10.1002\/14651858.CD005642.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"10","author":"Moher","year":"2012","journal-title":"International Journal of Surgery"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000370","article-title":"Interferon for interferon naive patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0096|cit96","unstructured":"United Network for Organ Sharing Chapter VI ; Liver and Intestine Transplantation in the United States, 1998-2007 optn.transplant.hrsa.gov\/ar2008\/chapter_iv_AR_cd.htm?cp=5"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","article-title":"State of the art in PEGylation: The great versatility achieved after forty years of research","volume":"161","author":"Pasut","year":"2011","journal-title":"Journal of Controlled Release"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep.20032","article-title":"Structural biology of hepatitis C virus","volume":"39","author":"Penin","year":"2004","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD005642.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1365-2036.2008.03685.x","article-title":"Glucocorticosteroids for alcoholic hepatitis \u2013 a Cochrane Hepato-Biliary Group Systematic Review with meta-analyses and trial sequential analyses of randomised clinical trials","volume":"27","author":"Rambaldi","year":"2008","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD005642.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"433\u20138","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C","volume":"33","author":"Reddy","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0101|cit101","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/S0168-8278(12)61166-0","article-title":"Peginterferon alpha-2A achieves higher early virological responses (RVR and CEVR) than peginterferon alpha-2B in chronic Hepatitis C: Meta-analysis of randomized clinical trials (RCT)","volume":"56","author":"Romero-Gomez","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1006\/jmbi.2001.5055","article-title":"Recent advances in the molecular biology of hepatitis C virus","volume":"313","author":"Rosenberg","year":"2001","journal-title":"Journal of Molecular Biology"},{"issue":"4","key":"10.1002\/14651858.CD005642.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/sim.2971","article-title":"Arcsine test for publication bias in meta-analyses with binary outcomes","volume":"27","author":"R\u00fccker","year":"2008","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"35","key":"10.1002\/14651858.CD005642.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"16","author":"Savovic","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"5","key":"10.1002\/14651858.CD005642.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"S1","key":"10.1002\/14651858.CD005642.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1478-3231.2008.01927.x","article-title":"The history of the \"natural history\" of hepatitis C (1968-2009)","volume":"29","author":"Seeff","year":"2009","journal-title":"Liver International"},{"issue":"S1","key":"10.1002\/14651858.CD005642.pub3-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/hep.1840360702","article-title":"National institutes of health consensus development conference: Management of hepatitis C: 2002","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s10620-011-1765-0","article-title":"Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of na\u00efve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials","volume":"56","author":"Singal","year":"2011","journal-title":"Digestive Diseases and Sciences"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0113|cit113","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0114|cit114","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for Trial Sequential Analysis (TSA) ctu.dk\/tsa\/files\/tsa_manual.pdf 1 115"},{"issue":"11","key":"10.1002\/14651858.CD005642.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","article-title":"Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time","volume":"57","author":"Trikalinos","year":"2004","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0116|cit116","first-page":"599","article-title":"Virus Taxonomy: The Classification and Nomenclature of Viruses","volume-title":"The Seventh Report of the International Committee on Taxonomy of Viruses","author":"Regenmortel","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses.","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","article-title":"Global surveillance and control of hepatitis C","volume":"6","author":"World Health Organization","year":"1999","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0120|cit120","unstructured":"WHO International Clinical Trials Registry Platform (ICTRP) www.who.int\/ictrp\/en\/"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"739029","DOI":"10.1155\/2013\/739029","article-title":"Efficacy and tolerability of peginterferon A-2a and peginterferon A-2b, both plus ribavirin, for chronic hepatitis C: A meta-analysis of randomized controlled trials","volume":"2013","author":"Yang","year":"2013","journal-title":"Gastroenterology Research and Practice"},{"key":"10.1002\/14651858.CD005642.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.clinthera.2010.08.009","article-title":"A comparison of peginterferon \u03b1-2a and \u03b1-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomised trials","volume":"32","author":"Zhao","year":"2010","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD005642.pub3-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005642.pub2","article-title":"Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C","author":"Awad","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005642.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005642.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T04:57:54Z","timestamp":1713934674000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005642.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":125,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005642.pub3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718293981.793492013","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]}}}